Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Novartis: RLX030 Improved Symptoms, Mortality In Heart Patients

Swiss drugmaker Novartis AG (NVS: Quote) Monday said results from a new analysis of the Phase III RELAX-AHF study indicate that the investigational medicine RLX030 or serelaxin consistently improved symptoms and mortality across multiple subgroups of patients with acute heart failure or AHFassessed in the trial.

The results were published today in the European Heart Journal and presented as a late breaker at the European Society of Cardiology congress in Amsterdam.

The addition of RLX030 to conventional treatment led to improvements in breathlessness and mortality at 6 months across all pre-specified subgroups including those with renal impairment, the elderly and patients with atrial fibrillation, although the small numbers of patients in each group limit the statistical conclusions that can be drawn.

Novartis said AHF patients require urgent treatment and that prompt decision-making to stop heart failure worsening is crucial in spite of patients often having diverse clinical profiles.

RLX030 is currently being assessed by health authorities around the world including the US Food and Drug Administration and the European Medicines Agency for the treatment of AHF. In June, the FDA granted RLX030 Breakthrough Therapy designation status, recognizing its potential to address a serious unmet medical need.

Register
To receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Pro-democracy demonstrations in Hong Kong demanding greater electoral reform entered the sixth day on Wednesday, which also marks China's 65th National Day. Thousands of protesters continue to occupy parts of downtown Hong Kong vowing not to leave until they achieve their goals. They want China... Employment in the U.S. private sector increased by more than expected in the month of September, according to a report released by payroll processor ADP on Wednesday, with employment rising by more than 200,000 jobs for the sixth straight month. After ending each of the two previous sessions modestly lower, stocks may see some further downside in early trading on Wednesday. The major index futures are currently pointing to a moderately lower open for the markets, with the Dow futures down by 34 points.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.